GLORIA GULMATICO: Open Payments
NPI 1942885546 · NORTHVALE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,714 in 86 payments from 19 companies in 2025. Trend: 2023 $519 · 2024 $2,154 · 2025 $1,714
Food & beverage: $1,646Consulting: $68
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $415 |
| GlaxoSmithKline, LLC. | 18 | $291 |
| Lilly USA, LLC | 8 | $149 |
| GENZYME CORPORATION | 7 | $145 |
| Novartis Pharmaceuticals Corporation | 6 | $136 |
| Genentech USA, Inc. | 5 | $91 |
| CSL Behring | 4 | $82 |
| ADMA BioManufacturing LLC | 4 | $68 |
| Organon LLC | 4 | $54 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $42 |
Products named: FASENRA, AIRSUPRA, TRELEGY ELLIPTA, DUPIXENT, EBGLYSS, NUCALA, Xolair, Rhapsido.
Industry payments across NJ — which companies pay providers there.
